₹108.2 crore as the covid-19 pandemic and the lockdowns imposed to curb it dragged sales of its medicines in India and US.The company’s consolidated revenue from operations were down 9% at ₹3,529 crore, with operating margins contracting 530 basis points (bps) to 14.7% in the quarter.
However, the margins were up 90 bps on a quarter-on-quarter basis.“The quarter’s performance was impacted by the covid-19 pandemic and related lockdowns, affecting our key businesses in India and US," Lupin managing director Nilesh Gupta said in a statement.“Despite the challenges impacting revenues, we improved margins driven by tight expense control.